Cargando…

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

Gastrointestinal (GI) malignancies are a major global health burden, with high mortality rates. The identification of novel therapeutic strategies is crucial to improve treatment and survival of patients. The poly (ADP-ribose) polymerase (PARP) enzymes involved in the DNA damage response (DDR) play...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhusaini, Abdullah, Cannon, Aoife, Maher, Stephen G., Reynolds, John V., Lynam-Lennon, Niamh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392860/ https://www.ncbi.nlm.nih.gov/pubmed/34440228 http://dx.doi.org/10.3390/biomedicines9081024

Ejemplares similares

Complement in Tumourigenesis and the Response to Cancer Therapy
por: O’Brien, Rebecca M., et al.
Publicado: (2021)

Altered Mitochondrial Function and Energy Metabolism Is Associated with a Radioresistant Phenotype in Oesophageal Adenocarcinoma
por: Lynam-Lennon, Niamh, et al.
Publicado: (2014)

Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference
por: Kennedy, Sean P., et al.
Publicado: (2022)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
por: Kim, Dae-Seok, et al.
Publicado: (2021)

Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma
por: Mongan, Ann Marie, et al.
Publicado: (2019)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype
por: Lynam-Lennon, Niamh, et al.
Publicado: (2016)

Potential of damage associated molecular patterns in synergising radiation and the immune response in oesophageal cancer
por: Donlon, Noel E, et al.
Publicado: (2023)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
por: Chan, Wei Yen, et al.
Publicado: (2021)

PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
por: Abecassis, Irina, et al.
Publicado: (2019)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation
por: Morrissey, Maria E., et al.
Publicado: (2020)

Is autophagy induction by PARP inhibitors a target for therapeutic benefit?
por: ELSHAZLY, AHMED M., et al.
Publicado: (2022)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
por: Sim, Hao-Wen, et al.
Publicado: (2022)

Thinking inside the box: intracellular roles for complement system proteins come into focus
por: O’Brien, Rebecca M., et al.
Publicado: (2023)

The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
por: Hunia, Jaromir, et al.
Publicado: (2022)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

The Protein Secretome Is Altered in Rectal Cancer Tissue Compared to Normal Rectal Tissue, and Alterations in the Secretome Induce Enhanced Innate Immune Responses
por: Heeran, Aisling B., et al.
Publicado: (2021)

Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma
por: Buckley, Amy M., et al.
Publicado: (2018)

Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells
por: Davern, Maria, et al.
Publicado: (2021)

PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
por: Franchet, Camille, et al.
Publicado: (2021)

Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer
por: Dasa, Siva Sai Krishna, et al.
Publicado: (2018)

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
por: Yuan, Yuan, et al.
Publicado: (2011)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
por: Lim, Joline S. J., et al.
Publicado: (2017)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
por: Barayan, Ranya, et al.
Publicado: (2020)

New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
por: Alemasova, Elizaveta E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pr2b0aheva1qa6bc4k24b244i8